Early approach to LDL-related risk after acute coronary syndrome: the OPTA project

References

• Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. DOI:10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. DOI:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639. DOI:10.1161/CIR.0000000000001052
   PubMed Web of Science ®Google Scholar
• Mendis S, Abegunde D, Yusuf S, et al. WHO study on prevention of recurrences of myocardial infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005;83(11):820–829.
   PubMed Web of Science ®Google Scholar
• Andres E, Cordero A, Magan P, et al. Long term mortality and hospital readmission after acute myocardial infarction: an eight-year follow-up study. Rev Esp Cardiol. 2012;65(5):414–420. DOI:10.1016/j.rec.2011.09.012
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–1119. DOI:10.1161/CIRCULATIONAHA.122.061620
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Psaltis PJ. Lipid lowering in acute coronary syndrome: is treatment early enough? JAMA. 2018;319(13):1325–1326.
   PubMed Web of Science ®Google Scholar
• Leucker TM, Blaha MJ, Jones SR, et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142(4):419–421. DOI:10.1161/CIRCULATIONAHA.120.046320
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–2462. DOI:10.1016/j.jacc.2019.08.010
   PubMed Web of Science ®Google Scholar
• Sionis A, Catapano AL, De Ferrari GM, et al. Improving lipid management in patients with acute coronary syndrome: the ACS lipid EuroPath tool. Atheroscler Suppl. 2020;42:e65–71.
   PubMed Web of Science ®Google Scholar
• Lopes RD, de Silva PG, de Andrade Jesuíno I, et al. Timing of loading dose of atorvastatin in patients undergoing percutaneous coronary intervention for acute coronary syndromes: insights from the SECURE-PCI randomized clinical trial. JAMA Cardiol. 2018;3(11):1113–1118. DOI:10.1001/jamacardio.2018.3408
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. DOI:10.1001/jama.285.13.1711
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504. DOI:10.1056/NEJMoa040583
   PubMed Web of Science ®Google Scholar
• Morales C, Plana N, Arnau A, et al. Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in lipid and vascular risk units. EROMOT study. Clin Investig Arterioscler. 2018;30(1):1–9. DOI:10.1016/j.artere.2017.07.005
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Gómez Doblas JJ, Barrios Alonso V. Control of LDL-C levels after an acute coronary syndrome in Spain. Are the available treatments adequately used? Rev Esp Cardiol (Engl Ed). 2021;74(2):194–196.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Suarez C, et al. Clinical Profile and management of patient patients with ischemic heart disease and/or peripheral artery disease in clinical practice: the APALUSA study. J Clin Med. 2022;11(12):3554. DOI:10.3390/jcm11123554
   PubMed Web of Science ®Google Scholar
• Barrios V, Soronen J, Carter AM, et al. Lipid management across Europe in the real-world setting: a rapid evidence review. Curr Med Res Opin. 2021;37(12):2049–2059.
   PubMed Web of Science ®Google Scholar
• Ferhatbegović L, Mršić D, Kušljugić S, et al. LDL-C: the only causal risk factor for ASCVD. Why is it still overlooked and underestimated? Curr Atheroscler Rep. 2022;24(8):635–642.
   PubMed Web of Science ®Google Scholar
• Buonvino C, Chopard R, Guillon B, et al. An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals. Eur Heart J Acute Cardiovasc Care. 2020;9(8):879–887. DOI:10.1177/2048872620912639
   PubMed Web of Science ®Google Scholar
• Escobar C, Anguita M, Arrarte V, et al. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol. Engl 2020;73(2):161–167. DOI: 10.1016/j.recesp.2019.07.024
   PubMed Web of Science ®Google Scholar
• Control lipidico [Computer software]. Version 1.0. Madrid: Sociedad Española de Cardiologia; 2020. [cited 22 Apr 2022]. Available at: https://control-lipidico.app/.
   Google Scholar
• Subirana I, Fernández Avilés F, Elosua R, et al. Interhospital variability in acute coronary syndrome management in the ATHOS study, Engl. Rev Esp Cardiol. 2019;72(8):691–693. DOI: 10.1016/j.recesp.2018.09.010
   Google Scholar
• Yong JW, Xing YY, Zhou MG, et al. Regional differences in the ratio of observed and expected in-hospital mortality for acute coronary syndrome patients in china: the improving care for cardiovascular disease in china-acute coronary syndrome project analysis. Angiology. 2022;73(4):357–364. DOI:10.1177/00033197211031323
   PubMed Web of Science ®Google Scholar
• Scicali R, Di Pino A, Platania R, et al. Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile. Nutr Metab Cardiovasc Dis. 2018;28(1):35–43. DOI:10.1016/j.numecd.2017.07.003
   PubMed Web of Science ®Google Scholar
• Mehta SR, Pare G, Lonn EM, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18(11):e888–896. DOI:10.4244/EIJ-D-22-00735
   PubMed Web of Science ®Google Scholar
• Abdullah SM, Defina LF, Leonard D, et al. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation. 2018;138(21):2315–2325. DOI:10.1161/CIRCULATIONAHA.118.034273
   PubMed Web of Science ®Google Scholar
• Castro A, Cosin J, Fernandez MR, et al. SEC-PRIMARIA. Chronic coronary syndrome process. [cited Jan 2023]. Available at: https://secardiologia.es/images/institucional/sec-calidad/sec-primaria/SEC_PRIMARIA_SCC_20220307.pdf
   Google Scholar
• Banach M, Penson PE, Vrablik M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499.
   PubMed Web of Science ®Google Scholar
• Holt N, Johnson A, de Belder M. Patient empowerment in secondary prevention of coronary heart disease. Lancet. 2000 Jul 22;356(9226):314.
   PubMed Web of Science ®Google Scholar
• Shi W, Ghisi GLM, Zhang L, et al. Systematic review, meta-analysis and meta-regression to determine the effects of patient education on health behaviour change in adults diagnosed with coronary heart disease. J Clin Nurs. 2022 Sep 11. Epub ahead of print DOI: 10.1111/jocn.16519
   Web of Science ®Google Scholar
• Ray KK, Ference BA, Séverin T, et al. World heart federation cholesterol roadmap 2022. Glob Heart. 2022;17(1):75. DOI:10.5334/gh.1154
   PubMed Web of Science ®Google Scholar